Trial Profile
A pilot study of intravenous, targeted-dose busulfan monotherapy as conditioning for autologous hematopoietic progenitor cell transplantation in high-risk AML [acute myeloid leukemia].
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Granulocyte colony-stimulating factors
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 29 Sep 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 27 Apr 2010 Actual patient number (3) added as reported by ClinicalTrials.gov.
- 09 Sep 2009 Actual end date changed from Nov 2008 to May 2009 as reported by ClinicalTrials.gov.